CAR-T treatment for advanced lung cancer with EGFR and CXCL13 signs
Part of Cancer, Lungs & breathing clinical trials.
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) must sign informed consent before any screening tests.
- You’re 18 to 75 years old, with advanced non-small cell lung cancer confirmed by lab tests or tumor samples.
- Your tumor testing must show EGFR is “positive” with an immunostaining score of 2+ or higher.
- Your tumor must show CXCL13 positivity in at least 10% of cells (from pathology testing).
- At least one tumor spot must be measurable on scans, and you must have expected survival of 12 weeks or more.
- Your body must be strong enough for treatment: good ECOG physical ability (0–1) plus acceptable heart, liver, kidney, and blood test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.